Published: December 11, 2008
/C O R R E C T I O N -- HealthLeaders-InterStudy/
In the news release issued by HealthLeaders-InterStudy over PR Newswire
December 10 with the headline "Downgraded Tier Positions and Step Therapy
Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension
Drug Market," we are advised by a representative of the company that the press
release contained an inaccurate headline and text. The corrected version of
the press release is below.
Novartis' Exforge and Daiichi-Sankyo's Azor Penetrate Preferred Brand Status
on U.S. Formularies Despite Many Pharmacy Directors' Preference for Using
Individual Drugs Over Fixed-Dose Combinations
Novel Agents Like Novartis' Tekturna Have Also Quickly Gained Preferred Brand
Tiering Despite Entering a Crowded and Highly Genericized Market, According to
a New Report from HealthLeaders-InterStudy
NASHVILLE, Tenn., Dec. 11 /PRNewswire/ -- HealthLeaders-InterStudy, a
leading provider of managed care market intelligence, issued an incorrect
press release on December 10 regarding the reimbursement status of Novartis'
Exforge and Tekturna hypertension agents. Far from having stalled in gaining
favorable access, these two agents have quickly penetrated Tier 1 and Tier 2
in U.S. formularies, with Exforge doubling the percentage of plans placing it
on these tiers in just one year, and Tekturna almost tripled the percentage of
plans giving it favored status. Likewise, the percentage of plans reimbursing
Daiichi-Sankyo's Azor as a Tier 1 and Tier 2 agent has grown dramatically as
well. The analysis includes a review of tier status of multiple plan types
including commercial, employers and pharmacy benefit managers; Medicare and
state Medicaid were excluded.
According to the new Formulary Forum report entitled Formulary Advantages
in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-
Dose Combinations, these gains have come despite reticence on the part of
pharmacy directors to reimburse some of these newer drugs.
"There may be a ceiling that these agents can reach in terms of favorable
tier placement," says Jason Labonte, Ph.D., vice president at HealthLeaders-
InterStudy. "Forty-four to 67 percent of managed care organization pharmacy
directors surveyed favor use of individual (and often generic) drugs versus
the newer single-pill, fixed-combination brands like Exforge and Azor.
However, the past year of gains in favorable reimbursement for these agents
certainly suggests they haven't hit that ceiling yet."
About Formulary Advantages in Hypertension: Penetration of Advantaged
Tiers by Novel Agents and Fixed-Dose Combinations
The new Formulary Forum report is based on a survey of 50 pharmacy
directors who control national, regional and state-level managed care
organizations (MCO). Answers were segmented by type of plan to illustrate
variances in strategy by size of plan. The easy-to-use PowerPoint format
allows users to cut-and-paste graphs and data into their own presentations.
About Formulary Forum
Formulary Forum is the first and only source for identifying the trends in
formulary positioning of competing agents, understanding why those trends were
taking place and predicting what changes lay ahead for brand positioning in
the face of both patent expiries and new drug launches. The new report series
from HealthLeaders-InterStudy combines historical formulary data from
Fingertip Formulary, which maintains the highest quality and most
comprehensive, integrated database of formulary information inthe United
States, with a robust survey of 50 MCO pharmacy directors. The pharmacy
directors responses reveal what events triggered movement of key brands within
their formulary for a specific disease as well as what moves they expect to
make in formulary structure as new brands enter the market.
About Fingertip Formulary
Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive
formulary data covering commercial, Medicaid, Medicare and PBM plans, among
others, inthe United States. Fingertip Formulary is a Decision Resources,
Inc. company.
About HealthLeaders-InterStudy
HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the
authoritative source for managed care data, analysis and news. For more
information, please visit www.HL-ISY.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision
Resources, Inc. companies. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Lisa Osgood Elizabeth Marshall
HealthLeaders-InterStudy Decision Resources, Inc.
781-296-2606 781-296-2563
losgood@hl-isy.com emarshall@dresources.com
------
Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge’s and Tekturna’s Growth in The Hypertension Drug Market
MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy
NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis’ Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge’s and Tekturna’s tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.
"The future reimbursement outlook for repackaging of individual hypertension agents is not that promising," according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo’s Azor.”
About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations
The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.
About Formulary Forum
Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information inthe United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.
About Fingertip Formulary
Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, inthe United States. Fingertip Formulary is a Decision Resources, Inc. company.
About HealthLeaders-InterStudy
HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Lisa Osgood Elizabeth Marshall
HealthLeaders-InterStudy Decision Resources, Inc.
781-296-2606 781-296-2563
losgood@hl-isy.com emarshall@dresources.com
SOURCE HealthLeaders-InterStudy
Copyright © 2012, PRNewswire
Copyright © 2012, NewsBlaze,
Daily News
Search News
Daily News
